The partial response
patients showed decrease in mean bilirubin levels at 6 months of follow-up period.
* Of nine patients with measurable disease, two patients achieved stable PSA and stable scans at 12 weeks; * Two patients had a stable PSA at 12 weeks but progressed radiographically; * One patient in the higher dose group demonstrated a partial response
on scans but PSA continued to rise; and * Side effects included hematologic, metabolic and hepatic side effects, neuropathy, syncope, diarrhea and fatigue.
The purpose of Experiment 4 was to determine whether animals made more partial responses
under high effort conditions than under low effort conditions in order to determine whether the animals pressing under high effort conditions were, in effect, on an effort-produced partial reinforcement schedule of reinforcement.
Further, patients who were refractory to both daratumumab and pomalidomide had an overall response rate of 29%, with 25% achieving a partial response
and one patient achieving a very good partial response
All the subjects of group A (100%) had partial response
, 30% of subjects partial response
and among group C subjects, 33.33% had no response and 66.67% had partial response
An additional six patients experienced a partial response
, defined as achieving improvement in at least one affected organ.
Initially, there was evidence of a partial response
to chemotherapy, and for 13 mouths, this antiblastic regimen appeared to slow the growth of the tumor.
To solve this problem, both formats have adopted high-efficiency Partial Response
Maximum Likelihood (PRML) technology, a well-proven disk- drive technique to enable higher recording densities that has recently started to appear in formats.
"In this trial, clinicians tended not to increase the sertraline dose for patients with partial response
, electing instead to allow more time with the same dose," they said.
One patient was cancer-free 10 months after therapy, in 11 patients the tumors shrank by more than 50 percent, and 10 patients had a partial response
- The US Food and Drug Administration has approved Lynparza for use as maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response
to 1st-line platinum-based chemotherapy, Anglo-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) and US-based Merck and Co., Inc., (NYSE: MRK) said.
The Phase III SOLO-one trial evaluated the product as a maintenance treatment for patients with newly-diagnosed and advanced BRCA-mutated (BRCAm) ovarian cancer, who have been in complete or partial response
following first-line standard platinum-based chemotherapy.